Orphanos Competitors

The National Organization for Rare Disorders (NORD), a 501(c)(3) organization, is an independent patient advocacy organization dedicated to helping individuals with rare diseases and the organizations that serve them. NORD, along with its 350+ patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient support services. NORD serves all stakeholders in the rare disease community, including patients and their families, patient organizations, researchers, medical professionals, medical students, and companies developing orphan products. NORD also works closely with many government agencies, most notably the National Institutes of Health (NIH) and the Food and Drug Administration (FDA). All NORD programs are focused on one ultimate goal: to improve the lives of individuals and families affected by rare diseases. NORD is the official U.S. sponsor of Rare Disease Day, an international observance day held on the last day of February each year. Its goals are to raise awareness for rare diseases and improve access to treatment and medical representation for individuals with rare diseases and their families. To learn more, visit rarediseases.org/rare-disease-day. To learn more, please visit the NORD website at www.rarediseases.org. You can also follow NORD on X at @RareDiseases.

Established in 1996, Patient Advocate Foundation has been breaking down healthcare barriers for patients diagnosed with chronic, life threatening and/or debilitating illnesses by ensuring they have access to care, preserving their financial stability and safeguarding their employment. As a nonprofit healthcare industry leader, PAF offers free bilingual support, education and guidance to patients nationwide, earning them their sixth consecutive Four Star Charity Rating by Charity Navigator.

The Alpha-1 Foundation (A1F) is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by Alpha-1 worldwide. A1F is a not-for-profit Florida corporation founded in 1995 by John Walsh, Sandy Lindsey, and Susan Stanley, three individuals diagnosed with Alpha-1. A majority of the Board of Directors are either diagnosed with Alpha-1 or have a family member diagnosed with Alpha-1. A1F has invested more than $100 million to support Alpha-1 research and programs at 130 institutions in North America, Europe, the Middle East, and Australia. Follow us on social media for up-to-date Alpha-1 news and information: Facebook - Alpha1Foundation Twitter - alphafriend Instagram - Alpha1Foundation